Interview with Manuel Reiberg, Manager Company Operations, Daiichi Sankyo…
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Address: Effingergasse 21, 1160 Vienna,Austria
Tel: +43 1 48586420
Web: http://www.daiichi-sankyo.at/
Daiichi Sankyo Austria GmbH is the Austrian affiliate of Daiichi Sankyo, a global pharmaceutical company that focuses on researching and marketing innovative medications. The company’s roots extend back to 1899 and the early days of industrialization of the pharmaceutical sector.
The company itself was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly €8.6 billion in fiscal year 2011, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. The company does business in nearly 60 countries around the world. Daiichi Sankyo’s world headquarters are in Tokyo, Japan.
The company’s roots in Europe extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. The company currently does business in 12 European countries including Austria. With nearly 2,500 employees, Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies located in Europe.
Striving for innovation is a central task of Daiichi Sankyo. Innovation is the fundamental requirement for achieving the corporate goal of developing pharmaceutical products that are the best in their class or for establishing a new class of active ingredients. Furthermore, the commitment to fulfill or exceed the high expectations of stakeholders regarding corporate services, information and organizational processes is based on innovation as a fundamental principle.
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of doctors and patients. In its research, the company aims to develop drugs that are either “Best-in-Class” or create a new class of therapeutic solutions.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for patients with thrombotic disorders and is focused on the discovery of novel oncology and cardiovascular-metabolic therapies.egulations. Detailed information about such drugs, such as the performance of our products may be provided only to medical professionals. For this reason, we can only give you an overview of our main products.
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
2012 represents the 123rd anniversary of Schülke&Mayr. There have been many changes over the years, but do you think the ideals and values of today reflect the original vision set…
What are the historical and strategic factors which position Austria as one of the best healthcare systems in the world today? The main principles of the Austrian health care system…
You have been with Bayer for almost 15 years. What would you say defines your loyalty to the company, and has the time so far met your original expectations? Bayer…
What have been the most significant developments as a result of the acquisition of Viatris by Meda Pharma in 2005? At that time Viatris was a small company, and there…
What initially attracted you to Biotest back in 2001 and what do you think attracts industry professionals to Biotest today? I started my pharmaceutical career at Behring in Austria, doing…
You previously worked as CSO for onepharm; what was the motivation for creating Savira? OS: When I was working at onepharm, the organization was focused on anti-influenza and anti-inflammatory drug…
You have been managing LEO Pharma’s Austrian operations since March 2012. How do you look back at these first few months? And what have been your first initiatives at the…
You have been the head of MSD’s Austrian operations since April 2009. Can you start by telling our readers about the evolution of the affiliate since the merger with Schering…
What have been the focus areas for the association in improving the wellbeing of the life science biotech industry and what have been the key milestones/achievements since 2008 in providing…
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed…
Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria…
See our Cookie Privacy Policy Here
